PF-592,379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which is under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction. Unlike some other less selective D3 agonists, a research study showed that PF-592,379 has little abuse potential in animal studies, and so was selected for further development and potentially human clinical trials.[1][2] Development has since been discontinued.[3]
Clinical data | |
---|---|
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
Chemical and physical data | |
Formula | C13H21N3O |
Molar mass | 235.331 g·mol−1 |
3D model (JSmol) |
|
| |
|